Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,703 | $1,766 | $1,830 | $2,006 |
| - Cash | $151,371 | $145 | $116 | $69 |
| + Debt | $31,422 | $32 | $32 | $34 |
| Enterprise Value | -$117,246 | $1,653 | $1,746 | $1,971 |
| Revenue | $192 | $165 | $150 | $174 |
| % Growth | 16.1% | 10.4% | -14% | – |
| Gross Profit | $144 | $149 | $134 | $148 |
| % Margin | 74.8% | 89.8% | 89.5% | 85% |
| EBITDA | -$37 | $33 | $18 | $45 |
| % Margin | -19.1% | 20.2% | 11.9% | 26% |
| Net Income | -$45 | $22 | -$12 | $15 |
| % Margin | -23.5% | 13.6% | -7.9% | 8.8% |
| EPS Diluted | -0.8 | 0.4 | -0.21 | 0.27 |
| % Growth | -300% | 290.5% | -177.8% | – |
| Operating Cash Flow | $0 | $59 | $31 | $44 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $58 | $30 | $44 |